Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis

Pathology

Volumn 43, Issue 5, 2011, Pages 420-432

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Carcinoma; Ovary; Pathogenesis; Typing

Indexed keywords

EID: 80052135846     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328348a6e7     Document Type: Review

References (100)

1. McCluggage WG. My approach to and thoughts on typing of ovarian carcinomas. J Clin Pathol 2008; 61: 152-63.
2. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8.
3. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-2005.
4. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008; 27: 161-74.
5. Nomura H, Tsuda H, Susumu N, et al. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 341-5.
6. Tavassoli FA, Devilee P, editors.World Health Organisation Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
7. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-4.
8. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010; 29: 203-11.
9. Koonings PP, Campbell K, Mishell Dr, et al. Relative frequency of primary ovarian neoplasms: A ten year review. Obstet Gynecol 1989; 74: 921-6.
10. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993; 3: 72-9.
11. Baak JP, Langley FA, Talerman A, Delemarre JF. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986; 8: 354-7.
12. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med 1987; 111: 819-29.
13. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS 1991; 99: 353-8.
14. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1996; 54: 54-8.
15. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002; 55: 27-31.
16. Miller K, Price JH, Dobbs SP, et al. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol 2008; 61: 652-7.
17. Silverberg SG. Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol 2000; 19: 7-15.
18. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol 1998; 70: 2-12.
19. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proponed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82: 893-901.
20. Wilkinson N, McCluggage WG. Datasets for the Histopathological Reporting of Neoplasms of the Ovaries and Fallopian Tubes and Primary Carcinomas of the Peritoneum. London: Royal College of Pathologists, July 2008.
21. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: The value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004; 203: 617-9.
22. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-8.
23. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003; 22: 37-41.
24. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-24.
25. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Can Res 2004; 64: 6915-8.
26. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutation are restricted to low-grade serous tumours. J Pathol 2004; 202: 336-40.
27. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-82.
28. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 2010; 22: 462-72.
29. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331-45.
30. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9.
31. Lee Y, Medeiros F, Mindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: Applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006; 13: 1-7.
32. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2007; 30: 230-6.
33. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-16.
34. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
35. Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010; 220: 5-6.
36. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
37. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007; 31: 1168-74.
38. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: A morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-12.
39. Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepitheliallined spaces pattern of invasion and the disorganised orphan papillae. Int J Gynecol Pathol 2010; 29: 507-12.
40. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007; 50: 773-9.
41. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, bcl2, her-2/neu and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005; 29: 1034-41.
42. Kobel M, Reuss A, Du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191-8.
43. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinomas of the ovary. J Pathol 2010; 221: 49-56.
44. Gershenson DM, Sun CC, Lu KH, et al. Clinical behaviour of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108: 361-8.
45. Folkins A, Jarboe E, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-73.
46. Hart WR. Mucinous tumors of the ovary: A review. Int J Gynecol Pathol 2005; 24: 4-25.
47. Lerwill MF, Young RH. Mucinous tumours of the ovary. Diagn Histopathol 2008; 14: 366-87.
48. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: Points of general agreement and persistent controversies regarding nomenculature, diagnostic criteria, and behaviour. Hum Pathol 2004; 35: 959-60.
49. Lee KR, Young RH. The distinction between primary and secondary mucinous carcinomas of the ovary: Gross and histologic findings in 50 cases. Am J Surg Pathol 2003; 27: 281-92.
50. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovary: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-93.
51. Lewis MR, Deavers MT, Silva EG, Malpica A. Ovarian involvement by metastatic colorectal adenocarcinoma: Still a diagnostic challenge. Am J Surg Pathol 2006; 30: 177-84.
52. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: A review with an emphasis on morphological and immunohistochemical features. Histopathology 2005; 47: 231-47.
53. Berezowski K, Stasny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996; 9: 1040-4.
54. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colon and breast origin. Comparison between a statistical and intuitive approach. J Clin Pathol 1999; 52: 283-90.
55. Park SO, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002; 33: 1078-85.
56. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinouscarcinomas involving the ovary: Comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006; 19: 1421-8.
57. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: Analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006; 30: 1130-9.
58. Fragetta F, Pelosi G, Cafici A, et al. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch 2003; 443: 782-6.
59. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005; 18: 19-25.
60. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: An immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol 2004; 12: 127-31.
61. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to 'pseudomyxoma peritonei'. Am J Surg Pathol 1995; 19: 1390-408.
62. Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol 1995; 8: 573-6.
63. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997; 16: 1-9.
64. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: Morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007; 31: 854-69.
65. Tabrizi AD, Kalloger SE, Kobel M, et al. Primary ovarian mucinous carcinoma of intestinal type: Significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 2010; 29: 99-107.
66. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: Are we ready for a nomenculature change? Int J Gynecol Pathol 2010; 29: 108-12.
67. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal and pancreaticobiliary epithelial cells. Cancer 1992; 69: 2131-42.
68. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: A clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004; 28: 1311-8.
69. Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: A clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol 2003; 22: 42-51.
70. Provenza C, Young RH, Prat J. Anaplastic carcinoma in mucinous ovarian tumors: A clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol 2008; 32: 383-9.
71. Baergen RN, Rutgers J. Mural nodules in common epithelial tumors of the ovary. Int J Gynecol Pathol 1994; 13: 62-72.
72. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: Gastrointestinal and seromucinous (endocervical- like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006; 25: 83-9.
73. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: An analysis of 124 cases. Mod Pathol 2006; 19: 97-105.
74. Kelly P, Archbold P, Price JH, Cardwell C, McCluggage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 2010; 63: 169-73.
75. Scott M, McCluggage WG. Current concepts in ovarian epithelial tumorigenesis: Correlation between morphological and molecular data. Histol Histopathol 2006; 21: 81-92.
76. Cantrecasas M, Villaneuva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 1997; 70: 1581-6.
77. Gemignani ML, Schlaerth AC, Bogomolnly F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-81.
78. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: Frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20: 133-9.
79. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000; 24: 1465-79.
80. Zaino RJ. Synchronous carcinomas of the uterine corpus and ovary. Gynecol Oncol 1984; 19: 329-35.
81. Tornos C, Silva EG, Ordonez NG, Gershenson DM, Young RH, Scully RE. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Am J Surg Pathol 1995; 19: 1343-53.
82. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology 2008; 53: 156-65.
83. Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-8.
84. Brachtel EF, Sánchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J, Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 2009; 29: 1322-9.
85. DeLair D, Oliva E, Koble M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases. Am J Surg Pathol 2011; 35: 36-44.
86. Sangoi AR, Soslow RA, Teng NN, Longacre TA. Ovarian clear cell carcinoma with papillary features: A potential mimic of serous tumor of low malignant potential. Am J Surg Pathol 2008; 32: 269-74.
87. Tan DS, Kaye S. Ovarian clear cell carcinoma: A continuing enigma. J Clin Pathol 2007; 60: 355-60.
88. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Eng J Med 2010; 363: 1532-43.
89. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: A morphologic study with emphasis on differential diagnosis. Am J Surg Pathol 2004; 28: 453-63.
90. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: Histogenetic and diagnostic implications. Am J Surg Pathol 2003; 27: 1434-41.
91. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: A review. Pathology 2007; 39: 134-8.
92. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol 2010; 34: 984-93.
93. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004; 23: 97-9.
94. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of theWilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158-63.
95. Al-Hussaini M, Stockman A, Foster H, McCluggage WG.WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-15.
96. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002; 117: 541-5.
97. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
98. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007; 38: 1074-80.
99. McCluggage WG. Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002; 55: 321-5.
100. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002; 12: 687-90.